Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-629P is a pseudogene of the U6 small nuclear RNA family found in the human genome. Pseudogenes resemble functional genes but typically lack the ability to code for a functional product. The functional U6 small nuclear RNA (U6 snRNA) is a highly conserved non-coding RNA essential for formation of the spliceosome, a complex responsible for excising introns from pre-mRNA during RNA splicing[1][3]. While the U6 snRNA gene family includes numerous functional and pseudogene loci in humans, RNU6-629P does not encode an active molecule and is generally annotated as non-functional. Some pseudogenes regulate their parental gene or act as competitive endogenous RNAs (ceRNAs), antisense RNAs, or sources of siRNAs that may influence gene expression[2]; however, no specific biological, clinical, or therapeutic role of RNU6-629P has been documented in the literature. It is not considered a therapeutic target, a receptor, nor does it have known interactions with approved drugs, known biomarkers, or safety concerns. Clarifications and issues ("is_incorrect"): - The entry RNU6-629P refers specifically to a pseudogene, not a receptor, enzyme, transporter, therapeutic target, or active molecule. - By convention, pseudogenes are not considered "targets" in drug discovery or therapeutic intervention unless specific functional or regulatory roles are proven, which is not the case here[2]. - There is no evidence of RNU6-629P being misspelled, but its inclusion as a drug target is incorrect; as a pseudogene, it does not fulfill the criteria. - U6 snRNA itself is functionally important, but RNU6-629P is just one of many pseudogenized copies and is not itself a true, functional molecule[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 629, pseudogene (RNU6-629P).